Management of hypertension for patients undergoing dialysis therapy

被引:0
作者
Taniyama Y. [1 ]
机构
[1] Division of Nephrology, Department of Internal Medicine, Kindai University Faculty of Medicine, 3772, Osakasayama,Osaka
关键词
Blood pressure measurement; Body fluid volume; Dry weight; Hemodialysis; Hypertension; Peritoneal dialysis; Reninangiotensin system; Residual renal function; Salt restriction; βblocker;
D O I
10.1186/s41100-016-0034-2
中图分类号
学科分类号
摘要
Hypertension is very prevalent among patients undergoing dialysis therapy: hemodialysis (HD) and peritoneal dialysis (PD). Although it is recognized as a great risk of cardiovascular mortality for these populations, how to regulate blood pressure (BP) is poorly understood. For HD patients, we should pay much attention to methods of measuring BP. Outofcenter BP levels and BP variability should be evaluated by ambulatory BP monitoring and home BP measurement because they are closely associated with cardiovascular mortality. Although target BP levels are not clear, several clinical guidelines suggest <140/90 mmHg. However, it must be determined for each individual patient with careful considerations about comorbidities. Based on the underling pathophysiology of hypertension in patients on dialysis, maintaining an appropriate volume of body fluid by dietary salt restriction and optimization of dry weigh should be considered as a first line therapy. Inhibitors for reninangiotensin system may be suitable to reduce BP and mortality for those patients on dialysis. These drugs may also be effective for preserving residual renal function and peritoneal function for PD patients. βblockers may have potentials to improve survival for HD patients and can be added to antihypertensive medications. Lacking largescale and good quality clinical trials, there are many questions to be answered. Much effort should continuously be made to create evidences for better management of hypertension for patients on dialysis therapy. © 2016 The Author(s).
引用
收藏
相关论文
共 75 条
[1]  
Agarwal R., Nissenson A.R., Batlle D., Coyne D.W., Trout J.R., Warnock D.G., Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States, Am J Med, 115, 3, (2003)
[2]  
Iseki K., Nakai S., Shinzato T., Et al., Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan, Ther Apher Dial, 11, 3, (2007)
[3]  
Longenecker J.C., Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE study, J Am Soc Nephrol., 13, (2002)
[4]  
Shafi T., Waheed S., Zager P.G., Hypertension in hemodialysis patients: An opinionbased update, Semin Dial, 27, 2, (2014)
[5]  
Roberts M., Pilmore H.L., Tonkin A.M., Et al., Challenges in blood pressure measurement in patients treated with maintenance hemodialysis, Am J Kidney Dis, 60, 3, (2012)
[6]  
Kuipers J., Usvyat L.A., Oosterhuis J.K., Et al., Variability of predialytic, intradialytic, and postdialytic blood pressures in the course of a week: A study of Dutch and US maintenance hemodialysis patients, Am J Kidney Dis, 62, 4, (2013)
[7]  
Agarwal R., Andersen M.J., Light R.P., Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients, Am J Nephrol, 28, 2, (2008)
[8]  
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients, Am J Kidney Dis, 45, 4, (2005)
[9]  
Hirakata H., Nitta K., Inaba M., Et al., Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis, Ther Apher Dial, 16, 5, (2012)
[10]  
Mc Causland F.R., Waikar S.S., Brunelli S.M., Et al., Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: The 58th annual fall conference and scientific sessions, Nephron Clin Pr, 113, 3, (2009)